Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are observing patients with Gaucher disease in the International Collaborative Gaucher Group ICGG Gaucher Registry to understand the diseases variability, progression, and natural history. The study aims to help guide treatment decisions and improve patient care by providing data on patient outcomes and the long-term effectiveness of treatments like imiglucerase and eliglustat. There is also a Gaucher Pregnancy Sub-registry focusing on pregnancy outcomes and infant growth in women with Gaucher disease. Participants in the Registry do not receive experimental treatments but continue with their usual clinical assessments and care as determined by their physicians. The Pregnancy Sub-registry collects data from pregnant women with Gaucher disease, including medical and obstetric history, pregnancy, birth details, and infant growth up to 36 months postpartum. Both registries do not involve any experimental interventions and support standard care practices. During the study, participants undergo routine clinical assessments and provide medical data as part of their ongoing care. Data collected includes patient outcomes, monitoring recommendations, and pregnancy-related information when applicable. The studys primary outcomes include generating monitoring guidelines for Gaucher disease and tracking pregnancy and infant growth outcomes. The registry is ongoing and international, with data collected over several decades to enhance understanding and optimize care for Gaucher disease.
Actively Recruiting
Researchers are evaluating how well seltorexant works and its safety when added to antidepressant treatment in adults and elderly participants with major depressive disorder who also experience insomnia symptoms. The study focuses on participants who have not adequately responded to treatment with selective serotonin reuptake inhibitors SSRIs or serotonin-norepinephrine reuptake inhibitors SNRIs. It aims to compare seltorexant with placebo as an additional therapy to improve depressive symptoms in this group. Participants will take seltorexant or a matching placebo orally once daily for 6 weeks during the double-blind phase of Part 1, while continuing their current SSRI or SNRI antidepressant. Those who complete Part 1 and meet criteria can enter Part 2, which includes open-label induction and stabilization phases where all receive seltorexant alongside their antidepressant. Participants who achieve a stable response then enter a double-blind maintenance phase in Part 2, receiving either seltorexant or placebo daily along with their antidepressant. During the study, participants will undergo assessments including depression rating scales like the Montgomery-Asberg Depression Rating Scale MADRS and patient-reported sleep disturbance measures. Researchers will monitor changes in depressive symptoms and sleep over time, track time to relapse during the maintenance phase, and evaluate safety. The total study duration may extend up to nearly three years for some participants, with follow-up after each treatment phase.
Actively Recruiting
Researchers are evaluating whether EP-088MM09, which contains modified house dust mite allergens called mannan-conjugated allergoids, can treat house dust mite allergy. This Phase 3 clinical trial involves 250 participants aged 12 to 65 years with persistent moderate to severe nasal allergy symptoms, with or without eye symptoms, and possibly mild or moderate controlled allergic asthma. The study aims to compare the treatments effect on allergy symptoms and the need for relief medicines against a placebo while assessing safety. Participants will be randomly assigned to receive either EP-088MM09 or a placebo, both given as subcutaneous injections. The treatment phase includes 12 monthly visits where participants receive injections under the skin the first visit involves two injections, and subsequent visits involve one injection each. Some participants sensitive to pollen may have an additional baseline visit to ensure symptom assessments avoid pollen season influence. After completing treatment, a final follow-up visit occurs about one month later. Throughout the study, participants will attend screening visits to confirm eligibility, complete daily symptom and medication diaries during specified periods, and provide blood samples and questionnaires on symptoms and quality of life. Clinic visits include monitoring of health and medication use, with participants staying at the clinic for at least 30 minutes after each injection. The main outcome measured is a combined score of symptoms and medication use over four weeks following treatment. Participation lasts approximately 14 to 21 months.